Detalles de la búsqueda
1.
Absolute Lymphocyte Count Predicts Immune-Related Adverse Events in Patients With Non-Small-Cell Lung Cancer Treated With Nivolumab Monotherapy: A Multicenter Retrospective Study.
Front Oncol
; 11: 618570, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34123782
2.
Prognostic Value of Baseline Medications Plus Neutrophil-to-Lymphocyte Ratio in the Effectiveness of Nivolumab and Pembrolizumab in Patients With Advanced Non-Small-Cell Lung Cancer: A Retrospective Study.
Front Oncol
; 11: 770268, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34820333
3.
Peripheral blood biomarkers predict immune-related adverse events in non-small cell lung cancer patients treated with pembrolizumab: a multicenter retrospective study.
J Cancer
; 12(7): 2105-2112, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33754009
Resultados
1 -
3
de 3
1
Próxima >
>>